CD274 and gastric cancer: By assessing PD-L1 protein expression by IHC, the current predictive biomarker used for selecting GC patients eligible for Pembrolizumab immunotherapy [16], we found that PD-L1 protein expression, evaluated in cancer cells, showed no significant differences between the two molecular subgroups.